Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
65 hedge funds and large institutions have $218M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 10 closing their positions.
76% more capital invested
Capital invested by funds: $124M → $218M (+$93.9M)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 68 → 65 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$4.77M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.75M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.71M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.54M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$831K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.06M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$600K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$525K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$388K |
SYRS Hedge Fund Activity: Q1 2019 in Review
65 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2019, worth a combined $218M — up 76% from $124M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SYRS and 7 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was Sumitomo Mitsui Trust Group, opening a new position worth an estimated $4.77M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.34M sold.
- 65 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2019, down from 68 in Q4 2018.
- Funds reported $218M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 76% quarter-over-quarter.
- 7 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 10 closed out, a net change of -3 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Sumitomo Mitsui Trust Group, an estimated $4.77M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Point72 Asset Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q1 2019.